Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NPL8
UPID:
TIDC1_HUMAN
Alternative names:
Protein M5-14; Translocase of inner mitochondrial membrane domain-containing protein 1
Alternative UPACC:
Q9NPL8; D3DN81; Q6IAJ7; Q6UWU6; Q9NPR3; Q9NPS5; Q9P0Y6
Background:
Complex I assembly factor TIMMDC1, mitochondrial, also known as Protein M5-14 and Translocase of inner mitochondrial membrane domain-containing protein 1, plays a crucial role in the assembly of the mitochondrial NADH:ubiquinone oxidoreductase complex (complex I). This protein is instrumental in constructing the membrane arm of complex I, essential for cellular energy production.
Therapeutic significance:
The protein is linked to Mitochondrial complex I deficiency, nuclear type 31, a condition with autosomal recessive inheritance. This disease manifests in a spectrum from lethal neonatal disease to adult-onset neurodegenerative disorders. Understanding the role of Complex I assembly factor TIMMDC1 could open doors to potential therapeutic strategies.